Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | pp65 Dendritic Cell Vaccine + Temozolomide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
pp65 Dendritic Cell Vaccine | pp65 DC Vaccine | Pp65 dendritic cell vaccine is a cancer vaccine composed of autologous dendritic cells modified to express pp65, which potentially results in increased immune response against pp65-expressing tumors (PMID: 25762141, PMID: 28411277). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02366728 | Phase II | pp65 Dendritic Cell Vaccine + Temozolomide | C Migration Study for Newly-Diagnosed GBM (ELEVATE) | Completed | USA | 0 |
NCT03688178 | Phase II | pp65 Dendritic Cell Vaccine + Temozolomide pp65 Dendritic Cell Vaccine + Temozolomide + Varlilumab | DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab (DERIVe) | Active, not recruiting | USA | 0 |